» Articles » PMID: 26670386

Suppression of Drug Resistance in Dengue Virus

Overview
Journal mBio
Specialty Microbiology
Date 2015 Dec 17
PMID 26670386
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Unlabelled: Dengue virus is a major human pathogen responsible for 400 million infections yearly. As with other RNA viruses, daunting challenges to antiviral design exist due to the high error rates of RNA-dependent RNA synthesis. Indeed, treatment of dengue virus infection with a nucleoside analog resulted in the expected genetic selection of resistant viruses in tissue culture and in mice. However, when the function of the oligomeric core protein was inhibited, no detectable selection of drug resistance in tissue culture or in mice was detected, despite the presence of drug-resistant variants in the population. Suppressed selection of drug-resistant virus correlated with cooligomerization of the targeted drug-susceptible and drug-resistant core proteins. The concept of "dominant drug targets," in which inhibition of oligomeric viral assemblages leads to the formation of drug-susceptible chimeras, can therefore be used to prevent the outgrowth of drug resistance during dengue virus infection.

Importance: Drug resistance is a major hurdle in the development of effective antivirals, especially those directed at RNA viruses. We have found that one can use the concept of the genetic dominance of defective subunits to "turn cousins into enemies," i.e., to thwart the outgrowth of drug-resistant viral genomes as soon as they are generated. This requires deliberate targeting of larger assemblages, which would otherwise rarely be considered by antiviral researchers.

Citing Articles

A Targeted Computational Screen of the SWEETLEAD Database Reveals FDA-Approved Compounds with Anti-Dengue Viral Activity.

Moshiri J, Constant D, Liu B, Mateo R, Kearnes S, Novick P mBio. 2020; 11(6).

PMID: 33173007 PMC: 7667029. DOI: 10.1128/mBio.02839-20.


Berberine Chloride is an Alphavirus Inhibitor That Targets Nucleocapsid Assembly.

Wan J, Brown R, Kielian M mBio. 2020; 11(3).

PMID: 32605989 PMC: 7327175. DOI: 10.1128/mBio.01382-20.


Antiviral Activity of Benzavir-2 against Emerging Flaviviruses.

Gwon Y, Strand M, Lindqvist R, Nilsson E, Saleeb M, Elofsson M Viruses. 2020; 12(3).

PMID: 32235763 PMC: 7150796. DOI: 10.3390/v12030351.


Discovery of a small molecule inhibitor targeting dengue virus NS5 RNA-dependent RNA polymerase.

Shimizu H, Saito A, Mikuni J, Nakayama E, Koyama H, Honma T PLoS Negl Trop Dis. 2019; 13(11):e0007894.

PMID: 31738758 PMC: 6886872. DOI: 10.1371/journal.pntd.0007894.


Viral RNA-Dependent RNA Polymerase Inhibitor 7-Deaza-2'--Methyladenosine Prevents Death in a Mouse Model of West Nile Virus Infection.

Eyer L, Fojtikova M, Nencka R, Rudolf I, Hubalek Z, Ruzek D Antimicrob Agents Chemother. 2019; 63(3).

PMID: 30642926 PMC: 6395895. DOI: 10.1128/AAC.02093-18.


References
1.
Kou Z, Quinn M, Chen H, Rodrigo W, Rose R, Schlesinger J . Monocytes, but not T or B cells, are the principal target cells for dengue virus (DV) infection among human peripheral blood mononuclear cells. J Med Virol. 2007; 80(1):134-46. DOI: 10.1002/jmv.21051. View

2.
Scaturro P, Trist I, Paul D, Kumar A, Acosta E, Byrd C . Characterization of the mode of action of a potent dengue virus capsid inhibitor. J Virol. 2014; 88(19):11540-55. PMC: 4178822. DOI: 10.1128/JVI.01745-14. View

3.
Balsitis S, Williams K, Lachica R, Flores D, Kyle J, Mehlhop E . Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog. 2010; 6(2):e1000790. PMC: 2820409. DOI: 10.1371/journal.ppat.1000790. View

4.
Marston H, Folkers G, Morens D, Fauci A . Emerging viral diseases: confronting threats with new technologies. Sci Transl Med. 2014; 6(253):253ps10. DOI: 10.1126/scitranslmed.3009872. View

5.
Kutsuna S, Kato Y, Moi M, Kotaki A, Ota M, Shinohara K . Autochthonous dengue fever, Tokyo, Japan, 2014. Emerg Infect Dis. 2015; 21(3):517-20. PMC: 4344289. DOI: 10.3201/eid2103/141662. View